MAIA Surges Amid Fed Chaos 🧬

“Beast mode” breakout continues...

December 10, 2025

Issuer-Sponsored Content from MAIA Biotechnology*

Been watching the markets this week — lots of noise, but one setup really stood out after the Fed move. I’ve been tracking it for a while now and it's showing the kind of strength that doesn't care what Powell says. Quick heads-up below 👇

TODAY’S TOP ALERT! 

MAIA Biotechnology (NYSE: MAIA)

👉  MAIA is TODAY’S #1 ALERT* 👈

Good afternoon, Folks,

The markets held their breath this morning waiting for the news from Fed Chair Powell…

CME’s FedWatch tool placed the odds of a quarter-point rate cut this time around at 90%, but for the January meeting, the odds of an additional cut were only 22%.

That set the stage for a potential market rally if the Fed signalled eagerness to cut further and sooner.

Ultimately, the Fed lowered rates by .25% basis points, as the market widely expected, though hinted that it will be cautious on further cuts in the future.

That was an immediate boost for the market, and you could almost feel the sigh of relief from traders.

In the meantime, I’ve been tracking a stock I thought was likely to outpace the “Pre-FOMC Announcement Drift” I wrote to you about yesterday.

MAIA Biotechnology, Inc. (MAIA)* has done that in spades.

I alerted it before the bell yesterday, and it went on to hit a 17% peak intraday:

With the Fed rate cut, as expected, and fresh news hot off the presses, MAIA just broke yesterday’s high and looks like it is setting up for a solid close once again.

As you can read in the link above, MAIA Biotechnology just announced that its lead drug candidate, ateganosine (THIO), is now aiming squarely at the $50 billion immunotherapy market for non-small cell lung cancer. 

The company believes THIO’s novel mechanism — targeting telomeres and activating immune response — could position it as a best-in-class treatment for late-stage patients. Based on updated data from its Phase 2 trial, MAIA plans to initiate a pivotal Phase 3 trial in 2025. 

The FDA has already granted Fast Track designation, opening the door for potential accelerated approval. If successful, THIO could be a first-in-class agent with broad implications across multiple difficult-to-treat cancers.

I’ve tracked this stock closely in 2025… alerting it 13 separate days, and it’s gone on to spike 10%+ all 13 times.

MAIA is still in full “bull mode” following yesterday’s big move.

I highly suggest that you keep this one on your radar and see where it goes next.

To Your Success,

*ISSUER-PAID DISCLAIMER: This entity is owned by Sherwood Ventures LLC (SV). To more fully understand any SV subscription, website, application or other service, please review our full disclaimer located at https://bullseyealerts.com/disclaimer/

Just so you know, what you're reading is curated content for which we have received a monetary fee (detailed below) to create and distribute. Let's be clear that investing can be quite the roller coaster as stock prices can have wild swings up and down, so consider those crucial risks before you ever consider trading anything we discuss. Make sure you check out our full disclosure down below for the details on how we were paid, the risks, and why these results aren't what you'd call “typical.”

Just a quick heads up about this ad you're reading—as we’ve said, even though we like the company referenced above, and all the facts we discussed above are true to the best of our knowledge, we are running a business here. To distribute this information and help offset the costs of maintaining our large digital audience, in advance of writing the content above, we currently have received sixty five thousand dollars (cash) from MAIA Biotechnology (via Sica Medi)a for advertising MAIA Biotechnology, Inc for a three day marketing program starting on December 9, 2025. Prior to this, we received twenty five thousand dollars (cash) from Sica Media for advertising MAIA Biotechnology, Inc for a one day marketing program starting on December 1, 2025. We also received fifteen thousand dollars (cash) from Sica Media for advertising MAIA Biotechnology, Inc for a one day marketing program starting on October 27, 2025. We also received fifteen thousand dollars (cash) from Sica Media for advertising MAIA Biotechnology, Inc for a one day marketing program starting on October 23, 2025, and we also received twenty five thousand dollars (cash) from Sica Media for advertising MAIA Biotechnology, Inc for a one day marketing program starting on October 2, 2025. Before this, we received twenty five thousand dollars (cash) from Sica Media for advertising MAIA Biotechnology, Inc for a one day marketing program starting on September 11, 2025. Before this, we received thirty five thousand dollars (cash) from Sica Media for advertising MAIA Biotechnology, Inc for a one day marketing program starting on August 27, 2025. Prior to this, we received twenty thousand dollars (cash) from Sica Media for advertising MAIA Biotechnology, Inc for a one day marketing program starting on July 28, 2025. Additionally, we were paid twenty five thousand dollars (cash) from Sica Media for advertising MAIA Biotechnology, Inc for a one day marketing program starting on July 1, 2025. Before this, we received thirty five thousand dollars (cash) from Sica Media for advertising MAIA Biotechnology, Inc for a one day marketing program starting on June 18, 2025.  Before this, we  received twenty five thousand dollars (cash) from Sica Media for advertising MAIA Biotechnology, Inc for a two day marketing program starting on May 1, 2025. Before this, we received fifteen thousand dollars (cash) from Sica Media for advertising MAIA Biotechnology, Inc for a one day marketing program on April 23, 2025. Prior to that, we received fifteen thousand dollars (cash) from Sica Media for advertising MAIA Biotechnology, Inc for a one day marketing program on March 20, 2025.  Before this, we received fifteen thousand dollars (cash) from Sica Media for advertising MAIA Biotechnology, Inc for a one day marketing program on February 27, 2025. Prior to that, we received thirty five thousand dollars (cash) from Sica Media for advertising MAIA Biotechnology, Inc for a one day marketing program on January 7, 2025, and we also received fifteen thousand dollars (cash) from Legends Media for advertising MAIA Biotechnology, Inc for a one day marketing program on December 16, 2024, and we received twenty-five thousand dollars (cash) from Sica Media for advertising MAIA Biotechnology, Inc for a one day marketing program on November 7, 2024, and also twenty-five thousand dollars (cash) from Sica Media for advertising MAIA Biotechnology, Inc for a one day marketing program on July 9, 2024 and also fifteen thousand dollars (cash) from Sica Media for advertising MAIA Biotechnology, Inc for a one day marketing program on June 13, 2024. Previously, we received twelve thousand five hundred dollars (cash) from Sica Media for advertising MAIA Biotechnology, Inc for a one day marketing program on June 7, 2024. Also, we were paid fifteen thousand dollars from Sica Media for advertising MAIA Biotechnology, Inc for a one day marketing program on March 6, 2024. We were also previously paid fourteen thousand dollars from Sica Media for advertising MAIA Biotechnology, Inc from a period beginning on November 15  through November 18, 2023, and also fifteen thousand dollars from Sica Media for advertising MAIA Biotechnology, Inc from a period beginning on October 12 through October 13, 2023. To date, we have received a total of five hundred twenty six thousand five hundred dollars for advertising MAIA Biotechnology, Inc.

These amounts were paid by someone else not connected to MAIA Biotechnology, Inc. It might be obvious, but whoever paid for this might own shares and is likely looking to sell some or all of them at any time after we send out this information, which might affect the stock price. We may also buy or sell shares in the company at some point in the future, although neither Sherwood Ventures nor its owners own any shares of the company at this time. Also, keep in mind that due to the sheer size of our audience, if even a small percentage of people decide they want to buy this stock, it could potentially boost interest enough to hike up those share prices and cause a temporary spike, and the opposite is possible as our program ends, though that is not always the case.

Now, diving right into MAIA Biotechnology, Inc might sound exciting. But remember, it’s like venturing into the wilderness—be aware that there's exceptional risk involved in trading. This isn't small potatoes we're talking about; you could lose every dime you put in, so always carefully think about what you’re doing. That’s why they call this trading, after all. We're shining a light on the good stuff about the company here, but it's on you to do your homework, make your own calls, and determine a plan for your own trading, hopefully with the help of your professional 1nvestment advis0r.

Oh, that brings us to another crucial point—we're not here to tell you (or even recommend) what you should do with your hard-earned money. We’re simply sharing our non-expert thoughts by highlighting some companies we like that could use some help telling their story to more people. We’re obviously biased in our writing. We’re not here to dig into anything that may be negative about the company; this is advertising, after all! Also, keep in mind that if we make some predictions about the future, these are technically known as “forward-L00king statements” under the securities acts, so take those with a grain of salt. As with all forecasts, they’re not set in stone, often wrong, and we certainly can’t know where the Company’s earnings, business, or share price will be tomorrow or a year from now.

Everything you read from us is all for your education, information, and possible entertainment. While we believe the info is reliable and accurate, we can't wear a cape and guarantee it. Before you jump into anything, make sure to talk it over with a pro—someone you trust who's licensed to give you real advice. To be clear, neither Sherwood Ventures nor its owners, employees, or independent contractors are registered as a secur1ties br0ker-dealer, br0ker, 1nvestment advis0r (IA), or IA rep’s with the SEC, any state securities regulat0ry authority, or any self-regulat0ry organization.

So, that's the scoop! If you're intrigued and want to learn more about the companies we talk about, hit up the SEC's website to dig into their filings and see the full picture.